Korean J Med.
2004 Oct;67(4):421-424.
Occurrence of tuberculous pleurisy associated with infliximab therapy
- Affiliations
-
- 1Department of Internal Medicine, Hallym University Sacred Heart Hospital, College of Medicine, Hallym University, Anyang, Korea. pulmoks@hallym.ac.kr
Abstract
- Infliximab is a chimeric antibody against tumor necrosis factor-alpha and it can be used in the treatment of ankylosing spondylitis. Tumor necorosis factor-alpha is a potent proinflammatory cytokine and plays a key role in the host response against tuberculosis. Infliximab is known to be effective on active ankylosing spondylitis but it can also cause reactivation of latent tuberculosis. Physicians should screen patients for latent tuberculous infection or disease before prescribing the drug. We experienced a case of tuberculous pleurisy after taking infliximab in a patient suffering from ankylosing spondylitis. We present the case with a review of literature.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Tuberculous Pleurisy: An Update
- A Study on pH and PCO2, in Tuberculous Pleurisy with Effusion
- A Case of Tuberculous Peritonitis in a Patient with Ankylosing Spondylitis during Infliximab Therapy
- Tuberculous Peritonitis in a Patient with Rheumatoid Arthritis Treated with Infliximab
- Tuberculous Pleurisy: Clinical Characteristics of Primary and Reactivation Disease
